Tag: GlobeNewswire

Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma

BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the launch of its inaugural Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program, an annual grant initiative designed to recognize and support early-career healthcare professionals advancing novel cell therapy approaches for the treatment of multiple myeloma. Applications are open through November 20, 2026.

“At Legend Biotech, we believe that advancing the future of cellular therapy requires continued investment in the people and ideas that will shape the field,” said Alan Bash, President, CARVYKTI. “Through the ELITE Program, we are supporting the next generation of innovators and research that can improve care for patients living with multiple myeloma, while we advance our pursuit of a cure.”

The ELITE Program is guided by an independent steering committee of nationally recognized experts in cellular therapy and hematologic malignancies, including Melissa Alsina, M.D., Ajai Chari, M.D., Rafael Fonseca, M.D., Sundar Jagannath, MBBS, Amrita Krishnan, M.D., Yi Lin, M.D., Ph.D., and Saad Usmani, M.D., MBA, FACP, FASCO. The committee provides scientific leadership and objective oversight of the grant applications and operates independently of Legend Biotech to guarantee a fair, transparent, and rigorous review process.

The program will award grants in two categories:

• Emerging Educator: Excellence in CAR-T Award, supporting projects with the potential to advance clinical practice, research, healthcare delivery, or education in multiple myeloma.
• Emerging Innovator: Innovation in CAR-T Award, supporting projects with an innovation “seed” specific to multiple myeloma that will serve as a pilot, expansion, or novel approach.

Recipients will be notified in December 2026 and invited to a recognition event in 2027, where they can present their proposals and engage with peers and members of the steering committee.

For more details on eligibility criteria, grant categories, and the application process, please visit the ELITE Program website.

ABOUT LEGEND BIOTECH
With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI^®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at www.legendbiotech.com and follow us on X, Instagram, and LinkedIn.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to statements relating to Legend Biotech’s advancement of its pursuit of a cure, the ELITE Program, including the timing and administration of the program, the grant application and selection process, the potential impact of the program on research, education, healthcare delivery, and innovation in multiple myeloma, and Legend Biotech’s plans, objectives, and expectations regarding future innovation and cell therapy development. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by Legend Biotech’s third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2026. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

INVESTOR CONTACT:
Caroline Paul
Tel: (973) 650-5832
Caroline.Paul@legendbiotech.com

PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
media@legendbiotech.com

MEXICO CITY, Oct. 01, 2026 (GLOBE NEWSWIRE) — Premier Graphene Inc. (OTC: BIEI) (the “Company” or “Premier”), together with its affiliate and strategic partner HGI Industrial Technologies S.A.P.I. de C.V. (“HGI”), today announced that payment was received on the first purchase order fulfilled by HGI and Premier for Mexico’s Secretaría de la Defensa Nacional (SEDENA).

The purchase order, documented under Remisión No. 001 dated May 8, 2026, involved the manufacture and delivery of 98 military waist belts (fajillas), consisting of:

• 35 units — Fajilla with TE-3A belt
• 35 units — Fajilla with NC belt
• 28 units — Fajilla with TE-3 belt

The fulfillment of these 3 separate contracts, while profitable, more significantly, demonstrated to the Mexican government, the professionalism of Premier and its team, coupled with the capacity to competently and expeditiously, deliver quality, compliant products and fulfill all responsibilities, paving the way to more significant and far more profitable contracts.

The accounting treatment, classification, and timing of any related revenue remains subject to determination by the Company’s management and independent auditors, in accordance with U.S. generally accepted accounting principles (GAAP).

HGI Industrial Technologies continues expanding its manufacturing and commercial operations in Mexico, while Premier Graphene Inc. is developing its position as a publicly traded company with exposure to advanced materials, graphene-related technologies, and strategic manufacturing opportunities.

“This payment marks another important milestone for HGI and Premier Graphene,” said Pedro A. Méndez, President of Premier Graphene Inc. and HGI Industrial Technologies S.A.P.I. de C.V. “Our focus has always been on turning opportunities into actual purchase orders, delivering the products, and ultimately converting those orders into collected revenue. Receiving payment is an important part of that process.”

The Companies expect to continue building upon their existing commercial relationships while pursuing additional opportunities in Mexico and international markets.

As part of their broader strategic development, HGI Industrial Technologies S.A.P.I. de C.V. and Nova Graphene Inc. are moving forward under a signed Joint Venture agreement focused on establishing a dedicated manufacturing plant in Mexico. The Joint Venture agreement was signed approximately one month ago, and the parties are currently awaiting financing to proceed with the planned facility. The facility is intended to support the production of advanced graphene-related and protective products for Mexico and international markets, subject to securing adequate financing. The planned plant is not yet operational.

Nova Graphene has tested and NIJ-certified ballistic plate products at Level III-A and Level IV, along with additional military applications and advanced materials. The planned manufacturing platform in Mexico is intended to build upon these existing technologies and capabilities and, if financed and established, could support production and commercial opportunities in Mexico, the United States, Europe, and Middle Eastern markets, subject to applicable financing, regulatory, and certification requirements.

Premier Graphene Inc. expects to pursue U.S. industrial and military procurement opportunities, including next-generation graphene-enhanced protective vests and other graphene-enhanced military products, as part of its broader North American market strategy. These activities are subject to Premier Graphene Inc. obtaining at least one type of required certification which has not yet been obtained. Despite the probability of receiving all such certifications, there can be no assurance that all will be received and thus all such opportunities will be realized.

About HGI Industrial Technologies S.A.P.I. de C.V.

HGI Industrial Technologies S.A.P.I. de C.V. is a Mexican technology and industrial solutions company focused on advanced materials, specialized manufacturing, graphene technologies, and related products serving commercial and strategic markets. HGI is a strategic partner and affiliate of Premier Graphene Inc.

About Premier Graphene Inc. (OTC: BIEI)

Premier Graphene Inc. (OTC: BIEI) is a publicly traded company focused on the commercialization and development of advanced materials, graphene technologies, industrial solutions, manufacturing, and related technologies through strategic partnerships and commercial initiatives.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the companies’ future business activities, anticipated commercial opportunities, planned manufacturing operations and the proposed manufacturing plant in Mexico, market development, and future revenue and profitability. Words such as “anticipates,” “expects,” “believes,” “plans,” “intends,” “may,” “will,” “could,” “should,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations, estimates, and assumptions and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, but not limited to, the timing and recognition of revenue; the companies’ ability to perform under, and collect payment on, purchase orders and contracts; changes in customer and governmental purchaser requirements; the receipt, timing, scope, and maintenance of regulatory certifications and authorizations, including export and import approvals; the availability of capital and financing for the planned manufacturing plant and other initiatives; competitive and market conditions; and other risks beyond the companies’ control. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and to review the companies’ public filings and disclosures. Premier Graphene Inc. and HGI Industrial Technologies S.A.P.I. de C.V. undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Media Contact:

Pedro Mendez, President
Premier Graphene Inc. / HGI Industrial Technologies S.A.P.I. de C.V.
Website: https://premiergrapheneinc.com/
Email: info@premiergrapheneinc.com
Investor Relations: info@premiergrapheneinc.com

PALO ALTO, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Game Your Game, Inc. (Nasdaq: GYGY) (“GYGY” or the “Company”), an AI-powered sports performance technology company, today announced that Soumya Das, Chairman and Chief Executive Officer, will participate in the Maxim Growth Summit 2026, taking place October 12–14, 2026 at the Hard Rock Hotel in New York, NY. Full conference details, including information on scheduling one-on-one meetings with management, can be found below.

Maxim Growth Summit 2026

Date: October 12 – 14, 2026

Location: Hard Rock Hotel, New York, NY

Attendees: Soumya Das, Chairman and CEO

Type: Investor Meetings

To schedule a one-on-one meeting with Game Your Game’s management team, please email KCSA Strategic Communications at GYGY@KCSA.com.

About Game Your Game, Inc.

Game Your Game, Inc. (Nasdaq: GYGY) is an AI-powered sports performance technology company. The Company develops and markets the GameGolf KZN AI™ platform — an integrated golf performance ecosystem of proprietary shot-tracking hardware and subscription-based software solutions. The platform leverages advanced GPS tracking, embedded neural network technology, and AI-powered analytics to provide golfers of all skill levels with real-time insights, on-course strategy recommendations, and personalized performance data. Game Your Game’s technology has been adopted by golfers in more than 140 countries, with over 36,000 golf courses mapped and an estimated 300 million shots tracked across the lifetime of its platform. The Company is headquartered in Palo Alto, California. For more information, visit www.gameyourgame.com. Altus Sports Group, Inc., a majority-owned subsidiary of Game Your Game, Inc., was formed to build a connected platform for the sports business across talent representation, athlete branding and sports marketing. For more information, visit www.altus-sports.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks and uncertainties, including, but not limited to, the Company’s participation in the Maxim Growth Summit 2026, the Company’s ability to execute its investor relations strategy and achieve its operational and financial objectives; and other factors identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Registration Statement on Form S-1 (File No. 333-296763) (as amended, the “Registration Statement”), which was declared effective by the SEC on July 28, 2026, and the final prospectus filed with the SEC pursuant to Rule 424(b)(4) that forms a part of the Registration Statement, and other periodic and current reports filed with the SEC from time to time and available for review at www.sec.gov. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. The Company undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this press release.

Investor and Media Contact

KCSA Strategic Communications

Phil Carlson, Managing Director

GYGY@KCSA.com

PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe. As a result, the exclusive European commercialization rights for D-PLEX₁₀₀ have reverted to PolyPid.

“We appreciate the collaboration with the ADVANZ PHARMA team over the past several years and thank them for working with us to reach a mutually agreeable conclusion,” said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. “Since entering into the original agreement in 2022, several transformative milestones have been achieved, including the successful completion of our Phase 3 SHIELD II trial, completion of our New Drug Application (“NDA”) submission to the US Food and Drug Administration (“FDA”), our EMA submission, and the establishment of our recently announced North American commercialization partnership with Azurity Pharmaceuticals . We believe that this makes D-PLEX₁₀₀ a highly attractive opportunity for multinational pharmaceutical companies looking to enhance their product portfolio in the surgical site infection space in Europe and other large markets.”

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its plans and expectations regarding the future commercialization of D-PLEX₁₀₀ in Europe following the termination of the ADVANZ PHARMA agreement, its evaluation of potential commercialization opportunities, the continued advancement of D-PLEX₁₀₀ toward potential regulatory approval and commercialization, and the potential role of D-PLEX₁₀₀ in improving surgical outcomes and addressing the burden of surgical site infections. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on February 25, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com

Delivery, reception and cleaning robots join HYTRON under Primech Vision, Primech’s integrated platform connecting robots, workforce and facility operations

Key Facts At-a-Glance

Who: Primech Holdings Limited (Nasdaq: PMEC), Singapore.

What: Unveils Primech Vision, a centralized platform that converts facility issues into tasks, assigns them to robots or facility personnel and tracks completion, and integrates delivery, reception and cleaning robots with HYTRON, Primech’s proprietary autonomous restroom-cleaning robot.

When: Pilot currently operating at Primech’s Singapore headquarters; live customer demonstrations are planned to begin in October 2026.

Where: Primech’s Singapore headquarters, where the Company plans to host visiting customers from Asia, Europe and the United States.

Why it matters: Primech Vision brings multiple robotic functions and facility personnel together within a common platform, moving Primech’s robotics offering beyond a single-task robot toward an integrated platform model.

Primech Holdings’ multi-robot facility fleet, featuring HYTRON alongside delivery, reception and cleaning robots at the Company’s Singapore headquarters. Image: Primech Holdings Limited.

SINGAPORE, Oct. 01, 2026 (GLOBE NEWSWIRE) — Primech Holdings Limited (Nasdaq: PMEC) (“Primech” or the “Company”), a technology-driven facilities services and AI robotics group, today unveiled Primech Vision, its centralized platform for coordinating robots and facility personnel, and announced the expansion of its robotics strategy beyond its proprietary HYTRON autonomous restroom-cleaning robot to a broader multi-robot fleet for the facilities management industry.

Primech Vision Platform

The expanded fleet includes delivery, reception and cleaning robots operating alongside HYTRON at the Company’s Singapore headquarters. Primech is integrating these robots with Primech Vision, its centralized platform that connects robots, the workforce and facility monitoring systems within a unified operating environment.

Primech Vision coordinates the identification, assignment, execution and verification of facility tasks. Through the platform, operational issues identified by robots, cameras or facility personnel can be converted into tasks and assigned to either robotic systems or human team members. Task progress and completion are then monitored through a centralized interface, giving facility managers a single view of task status and completion across a site.

By bringing multiple robotic functions together within a common platform, Primech aims to enable robots and facility personnel to operate as part of an integrated workforce rather than as standalone systems.

Pilot Program and Customer Demonstrations

The Company is initially piloting the integrated fleet at its Singapore headquarters, drawing on its facilities management operating experience to evaluate robot deployment, workflow integration and human-robot collaboration in a live operating environment.

Primech plans to begin hosting live demonstrations for visiting customers from Asia, Europe and the United States at its Singapore headquarters in October 2026.

Management Commentary

“Facilities management is our core business, and that gives us a practical understanding of where robotics can create meaningful operational value,” said Ken Ho, Chairman and Chief Executive Officer of Primech Holdings Limited. “HYTRON was developed from our experience addressing real operational challenges in the facilities management industry. We are now taking the next step by bringing different types of robots together with our workforce through a common platform.”

“Our vision is not simply to deploy more robots, but to create an integrated operating environment where people and robots can work together effectively. By piloting this model within our own operations first, we can refine the technology and workflows before introducing them more broadly to our customers.”

About Primech Holdings Limited

Primech Holdings Limited (Nasdaq: PMEC) is a Singapore-headquartered, technology-driven facilities services and AI robotics group with operations in Singapore and Hong Kong. Through its subsidiaries, the Group provides cleaning, facilities maintenance, stewarding, waste management and pest control services to public and private sector clients.

Through its subsidiary Primech AI, the Group develops HYTRON, an autonomous restroom-cleaning robot that combines AI perception with robotic manipulation. The Group also operates HomeHelpy, a digital home-services booking platform serving the consumer market. Primech Holdings was incorporated in 2020 and listed on the Nasdaq Capital Market in October 2023. For more information, visit investor.primechholdings.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, for example, statements regarding the Company’s development, integration, testing and deployment of robotic solutions and the Primech Vision platform, the timing, scope and results of pilot programs and customer demonstrations, adoption of technology-driven solutions, human-robot collaboration, and future business strategies, growth and expansion. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. These forward-looking statements are also based on assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2026, filed with the SEC on July 29, 2026, and its other filings with the SEC.

Investor Relations

Primech Holdings Limited
ir@primechholdings.com
www.primechholdings.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/45c05876-232d-4ff2-88b8-8179bd20f0f0

On the strength of these results, definitive agreement with the testing company being finalized; its name, business and the full agreement to be disclosed within weeks.

Ness Ziona, Oct. 01, 2026 (GLOBE NEWSWIRE) — QTREX Quantum Ltd. (Nasdaq: QTEX) (“QTREX” or the “Company”), a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced the results of independent testing of its AME cryogenic interconnect by one of the quantum computing industry’s leading companies. The testing company conducted separate microwave transmission tests at 20 millikelvin in its own cryogenic system, using its own instruments, reference cables and calibration standards. The results confirm the interconnect’s microwave performance at an operating temperature of superconducting quantum processors. On the strength of these results, QTREX and the testing company are finalizing a binding definitive agreement.

Key results:

• Channel-to-channel isolation better than 100 dB across the 4 to 8 GHz qubit band, between adjacent channels on a 0.34 millimeter pitch over a 15 centimeter run. No crosstalk was detected above the instrument’s noise floor in any tested channel pair, adjacent or not. This exceeds the published 40 dB channel to channel crosstalk specification of leading flexible cryogenic cabling by more than 60 dB.
• Channel-to-channel phase matching at 20 millikelvin. Cryogenic testing confirmed that channels formed together in a single monolithic AME body remain phase matched, supporting precise coordination of microwave signals for qubit control and readout.
• Impedance held constant along the entire line, with reflections from the line itself below 55 dB from 2 to 15 GHz, a uniformity previously seen only in machined coaxial cable.
• Insertion loss at 20 millikelvin of approximately 1 dB at 1 GHz and 2 dB at 6 GHz, including connectors. Cooling from room temperature reduced insertion loss, expressed in dB, by approximately a factor of three.
• Performance unchanged across repeated cooldowns. The channels measured at 20 millikelvin returned the same results in a second cooldown after warming to room temperature.
• RF performance unchanged under significant bending and after vacuum exposure, with X-ray and optical inspection showing no cracks, delaminations or subsurface defects.

Every qubit needs several microwave lines running down to 20 millikelvin. Today’s thousand qubit machines already carry thousands of hand-assembled coaxial cables, and the million qubit machines the industry is building toward cannot be wired that way. Dense, monolithic interconnect that isolates every channel, holds the channels in phase with one another and performs at 20 millikelvin is the missing piece. QTREX’s additively manufactured interconnect delivers it.

QTREX’s architecture places fully shielded channels about a third of a millimeter apart, close to 30 channels per centimeter of width, with every shield wall shared between neighboring channels. Radio frequency current flows within about a micron of a conductor’s surface, while every micron of metal conducts heat, so the thin shared walls carry the signal without the excess metal that carries heat. By design, the interconnect conducts about half the heat of an equivalent coaxial cable into the cooling stages, and less than the published figures of leading flexible cryogenic cabling at the millikelvin stages, where cooling power is scarcest.

“The coldest, most unforgiving environment in computing. One of the most exacting teams in our industry. Their instruments, their cryogenic system, their reference cables. That is the test, and these are the results,” said Dagi Ben-Noon, Chief Executive Officer of QTREX Quantum. “We view 60 decibels more isolation than the leading flexible cabling on the market as not an improvement but a different category, and it is what a million qubit machine will require.”

QTREX and the testing company are finalizing a binding definitive agreement. The Company expects to disclose the testing company’s full name, its field of activity and the agreement in full within weeks. The Company also expects to announce additional agreements with several companies in quantum computing in the fourth quarter of 2026.

About QTREX Quantum

QTREX Quantum Ltd. (Nasdaq: QTEX) is a technology company focused on advanced connectivity and electronics manufacturing solutions for quantum computing and other advanced hardware markets. Following its acquisition of the AME platform, the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. The Company also continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business.

For more information, please visit: www.q-trex.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected benefits of the testing results; that it is finalizing a binding definitive agreement with the testing company and expects to announce the contents of the agreement and the name of the party in the coming weeks; the belief that a dense, monolithic interconnect that isolates every channel, holds the channels in phase with one another and performs at 20 millikelvin is the missing piece and that its additively manufactured interconnect delivers it; that it views 60 decibels more isolation than the leading flexible cabling on the market as not an improvement but a different category, and it is what it believes a million qubit machine will require; and that it expects to announce additional agreements with several companies in quantum computing in the fourth quarter of 2026. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements. More detailed information about the risks and uncertainties affecting the Company is contained under “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission.

 

CONTACT: QTREX Quantum
Email: info@q-trex.com
Phone: +972-9-9664487

Míla Holding hf.
Storhofdi 22-30,

110 Reykjavik,

Iceland

Míla Holding hf.: Confirmation of the report on the financial obligations of MILA 300929 bond

Enclosed is a confirmation by KPMG ehf. on Míla Holding hf.’s report on financial obligations relating to the issuance of MILA 300929 bond. The Consolidated Condensed Interim Financial Statements for the six months ended June 30, 2026, of Míla Holding hf. Were published on September 23, 2026. The calculation and confirmation of financial conditions shall be carried out following the publication of the company’s annual accounts and the issuance of MILA 300929 bond.

The review of financial obligations by KPMG ehf. was in accordance with Míla Holding hf.’s assessment and a report on financial obligations was therefore confirmed.

For more information please contact:

Inga Helga Halldórudóttir

Compliance officer

Míla Holding hf.

ingah@mila.is

Attachments

• 2026-10-01 Compliance Certificate ID
• 20260110_Míla Holding hf. Press Release – Compliance Certificate

September 29 shipment follows successful customer inspection and approximately $1.77 million in customer payments received

MANKATO, Minn., Oct. 01, 2026 (GLOBE NEWSWIRE) — Easy Environmental Solutions, Inc. (OTC: EZES) today announced that its first commercial EasyFEN™ system has shipped from the Company’s Mankato, Minnesota, facility for deployment in Kenya.

The EasyFEN is a modular production system designed to manufacture Terreplenish®, a liquid microbial fertilizer with more than a decade of commercial use, at commercial scale using locally available crop waste and organic feedstocks.

The shipment marks the project’s transition from U.S.-based construction, testing and validation into commercial deployment in Kenya.

Ahead of shipment, a representative of the Kenyan customer traveled to Mankato, observed the EasyFEN operating and completed an on-site pre-shipment inspection. The inspection was completed successfully.

EZES has received approximately $1.77 million in previously announced customer payments associated with the EasyFEN system being deployed to Kenya.

“For years, the EasyFEN has been an engineering story. Today it becomes a deployment story,” said Nate Carpenter, Vice President of Sales, Africa, the Middle East & Europe. “It has been built, operated and inspected by the customer. It is now on its way to Kenya. From here, the milestones are simple: arrive, install, commission and produce. Each one moves us closer to replacing projections with actual in-market operating data.”

EasyFEN Organic ”Fertilizer Plant in a Box” loaded for transport to Kenya

From Shipment to Commercial Operation

Following ocean transit and customs clearance, the EasyFEN will move through site integration, installation, testing and commissioning.

Based on the current project schedule, EZES is targeting initial production approximately three months after shipment, subject to shipping conditions, customs clearance, site readiness and commissioning requirements.

As the deployment progresses, the Company expects to provide milestone-based public updates covering arrival in Kenya, installation and site integration, commissioning and first production, and ultimately initial commercial operating data.

Each stage is intended to provide an additional measure of commercial execution as the project moves toward full operation.

Commercial-Scale Local Fertilizer Production

The EasyFEN is designed to produce up to approximately 2.7 million gallons of Terreplenish® annually, depending on feedstock quality and operating conditions. Under standard application assumptions, that production could treat up to approximately 1.35 million acres per year.

Terreplenish is a liquid microbial fertilizer that has been on the market for more than a decade and has been evaluated through more than 100 independent studies conducted in the United States. Available field evidence indicates an agronomic contribution equivalent to approximately 45–60 pounds of nitrogen per acre and 15–20 pounds of phosphorus availability per acre.

Independent replicated research led by Dr. K. Bruce Kirksey at Agricenter International demonstrated that conventional nitrogen inputs could be reduced while maintaining or improving crop yields.

In Kenya, replicated trials submitted to the Kenya Plant Health Inspectorate Services (KEPHIS) reported double-digit yield increases in maize and tomatoes across three growing seasons compared with untreated controls.

In Southern Ghana, research conducted under irrigated rice-production conditions reported an approximately 11.9% increase in rice yield while using only 50% of the recommended inorganic fertilizer rate, increasing grain yield from 7.92 to 8.86 metric tons per hectare — nearly one additional metric ton of rice per hectare.                “The economics of the EasyFEN are driven by converting locally available crop waste into a higher-value agricultural input,” said Mark Gaalswyk, CEO of Easy Environmental Solutions. “Based on our current operating and production models, we believe the customer’s capital investment in an EasyFEN system has the potential to be recovered within the first year of commercial operation. Kenya will now allow us to measure actual production, operating costs, uptime and product deployment over the first several months of commercial operation and compare those results directly against our models.”

Rather than relying exclusively on fertilizer produced thousands of miles from where it will ultimately be used, the EasyFEN model is designed to establish production capacity inside individual markets using locally available feedstocks.

Its modular design allows additional systems to be added as demand develops, creating the potential for distributed fertilizer-production networks across regions and countries.

“If the Kenya data validates the economics we’ve modeled, the implications are significant,” said Bakry Osman, Director of Africa. “A system that can potentially return a customer’s capital within a year changes the conversation around expansion. At that point, the question becomes how quickly the market wants more.”

Kenya represents the first commercial deployment of that model.

The Next Proof Point

Once commissioned, the Kenya system is expected to give EZES its first opportunity to evaluate the performance and economics of an EasyFEN operating in Kenya.

At full utilization, the Company’s current internal models indicate the potential for annual recurring revenue to EZES from inoculant sales and monitoring fees to reach eight figures. Those same models indicate that, depending on realized fertilizer pricing, operating costs and product sell-through, local operators could potentially generate eight-figure annual operating profits.

These figures are modeled projections and are not guarantees of future performance. Actual results will depend on utilization, feedstock quality, realized pricing, operating expenses, market demand and the ability to sell the fertilizer produced.

The Company expects future operating data to include production throughput, system performance, operating costs, product deployment and other commercial metrics as they become available.

For EZES, that represents an important transition from engineering assumptions and modeled economics toward measurable commercial results.

The EasyFEN is built. The customer inspection is complete. It has shipped. The next proof point is in Kenya.

About Easy Environmental Solutions

Easy Environmental Solutions, Inc. (OTC: EZES), is an innovative company developing modular technologies to solve major world problems. With a strong goal for sustainability and efficiency, EZES aims to provide solutions for various industries through its unique approach to manufacturing and technology development.

www.easyenviro.com

www.terreplenish.com

952-400-6045

Forward-Looking Statements

This press release contains discussions that may constitute ‘forward-looking’ statements. Often these statements contain the words “believe,” “estimate,” “project,” “expect” or similar expressions. These statements are made in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.

Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company’s current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company’s periodic reports filed with OTC Markets. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact

Mark Gaalswyk – mark@easyenviro.com
Nate Carpenter — ncarpenter@easyenviro.com
Media/Corporate Contact — charlie@easyenviro.com
www.easyenviro.com
www.easyenergysystems.com
www.easyenergyfinance.com
Phone: 952-400-6045
Email: info@easyenviro.com

Source: Easy Environmental Solutions, Inc.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/454092a0-7a1e-455a-beaf-f8bfb811db3d

https://www.globenewswire.com/NewsRoom/AttachmentNg/80940884-c6e3-4747-a8a8-a1d5af5db48f

SARASOTA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (Nasdaq: ROP) announced that Abhijit Dubey has joined the Company’s Board of Directors.

Mr. Dubey is Chief Executive Officer and Chief AI Officer of NTT DATA, Inc., a global business and technology services company. He also serves as a Director of NTT DATA Group Corporation, the publicly listed parent company of NTT DATA, Inc. In his current role, Mr. Dubey leads NTT DATA’s strategy, growth, and operating performance, as well as the company’s enterprise-wide AI strategy and its transformation toward an AI-native operating model.

Prior to his current role, Mr. Dubey served as Chairman and Global Chief Executive Officer of NTT Ltd. Before joining NTT, he spent more than 20 years at McKinsey & Company, including as a Senior Partner, where he was a core leader of the firm’s global Technology, Media, and Telecommunications Practice and founded McKinsey’s cloud computing practice.

“Abhijit’s experience leading a large, global technology organization through an AI-driven transformation makes him a great fit for our Board,” said Neil Hunn, Roper Technologies’ President and CEO. “His perspective on enterprise software, AI adoption, and scaling technology businesses globally will be a valuable addition as we continue to grow our portfolio of vertical market software and technology enabled product businesses.”

“Abhijit brings a rare combination of large-scale operating experience with technology and AI leadership to our Board,” said Amy Woods Brinkley, Roper Technologies’ Board Chair. “We are confident that his background will support Roper’s governance as we continue to execute on our long-term strategy.”

About Roper Technologies

Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 500. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market leading businesses that design and develop vertical software and technology enabled products for a variety of defensible niche markets. Roper utilizes a disciplined, analytical, and process-driven approach to redeploy its excess capital toward high-quality acquisitions. Additional information about Roper is available on the Company’s website at www.ropertech.com.

Contact information:
Investor Relations
941-556-2601
investor-relations@ropertech.com

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — AIB Data Centers Inc. (NYSE American: AIB), a developer and operator of digital infrastructure focused on AI hosting and high-performance computing workloads, today announced that the Company will host a corporate update and presentation today, Thursday, October 1, 2026, at 4:15 p.m. Eastern Time.

Jerry Tang, Chief Executive Officer, and Jolienne Halisky, Chief Financial Officer, will host the presentation, which will be followed by a question-and-answer session.

The corporate update follows the Company’s recently announced contract for AI data center capacity and management plans to discuss:

• The recently announced agreement for 50 MW of critical IT capacity at CLT1
• CLT1’s power and development milestones;
• The expected timeline for delivering the first two data halls;
• Its anticipated approach to funding CLT1 development;
• AIB’s broader site portfolio and growth strategy

Presentation: Thursday, October 1, 2026
Time: 4:15 p.m. Eastern Time
Presentation Registration: Here
Attendees: Jerry Tang, Chief Executive Officer, Jolienne Halisky, Chief Financial Officer

A replay link will be emailed to all registrants following the conclusion of the event and the presentation used for this event can be found here.

About AIB Data Centers

AIB Data Centers Inc. is a developer and operator of digital infrastructure focused on AI hosting and high-performance computing workloads. The Company’s platform combines access to reliable, scalable power resources with modular infrastructure deployment designed to accelerate the development of next-generation compute capacity.

For more information, visit https://www.aib.us/.

Investor Relations

MZ Group – MZ North America
AIB@mzgroup.us